Vaxess Receives $6 Million from Gates Foundation to Develop Microneedle Patch Vaccines

BOSTON, Massachusetts—March 1, 2017—

Vaxess Technologies, Inc., an innovative life sciences company developing novel vaccine stabilization and delivery technologies, received two grants from the Bill & Melinda Gates Foundation to advance the development of inactivated polio (IPV) and live attenuated measles rubella (MR) vaccines using the company’s MIMIX™ sustained-release microneedle patch platform.

For more information, please see the full press release at Yahoo Finance and related coverage by the following outlets:

Genetic Engineering & Biotechnology News

Drug Delivery Business News

BioPharma-Reporter

American Council on Science and Health

Inside Philanthropy